{
  "abstract": "Background: Inflammatory bowel disease (IBD) and hidradenitis suppurativa (HS) frequently coexist and share overlapping immune pathways, yet comparative real-world outcomes between IL-12/23 or IL-23 inhibitors and Janus kinase (JAK) inhibitors in this population remain poorly defined.\n\nMethods: We conducted a retrospective cohort study using a large, multicenter, real-world dataset. Adults (≥16 years) with IBD and HS who initiated an IL-12/23 or IL-23 inhibitor after anti-TNF therapy or a JAK inhibitor were included; patients with prior exposure to the opposing drug class were excluded. Propensity score matching (1:1) yielded 150 patients per cohort. Outcomes from 30-365 days included acute care utilization, corticosteroid use, IBD complications, and overall and hidradenitis-specific antibiotic use.\n\nResults: After propensity score matching, 300 patients were included (150 per cohort; mean age 38 years; 75.3% female). Rates of emergency department visits or hospitalization were similar between groups (RR 1.20, 95% CI, 0.82-1.77). Corticosteroid use risk was numerically higher in the IL-12/23 or IL-23 cohort (RR 1.20, 95% CI, 0.98-1.46). IBD-related complications did not differ significantly (RR 1.06, 95% CI, 0.58-1.93). Overall antibiotic use was comparable, while hidradenitis-specific antibiotic use was higher in the IL-12/23 or IL-23 cohort (RR 1.47, 95% CI, 1.11-1.95).\n\nConclusions: In this real-world analysis, IL-12/23 or IL-23 inhibitor therapy was associated with higher hidradenitis-specific antibiotic use and numerically greater but statistically nonsignificant corticosteroid exposure, while hospitalization and IBD-related complications were comparable. These findings should be interpreted cautiously given the absence of validated disease-activity measures; prospective studies are needed to inform optimal therapeutic selection.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 4,
  "authors": [
    {
      "name": "Youssef Hafez",
      "orcid": "0000-0003-4205-3074"
    },
    {
      "name": "Ali Osman",
      "orcid": "0000-0003-0226-8230"
    },
    {
      "name": "Wing-Kin Syn",
      "orcid": "0000-0001-7966-0500"
    },
    {
      "name": "Manar Shmais",
      "orcid": "0000-0001-6924-6533"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/5apzj33j3e24d.bib",
  "cited_by": 0,
  "doi": "10.1093/crocol/otag086",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13735508/",
  "id": "5apzj33j3e24d",
  "issns": [
    "2631-827X"
  ],
  "landing_url": "https://doi.org/10.1093/crocol/otag086",
  "language": "en",
  "licence": "CC-BY-NC-4.0",
  "licence_label": "CC BY-NC 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "AcademicSubjects/MED00260"
    ],
    [
      "heading",
      "AcademicSubjects/MED00760"
    ],
    [
      "heading",
      "AcademicSubjects/MED00972"
    ],
    [
      "heading",
      "Observations and Research"
    ],
    [
      "openalex",
      "2715|Inflammatory Bowel Disease"
    ]
  ],
  "openalex": "W7225320374",
  "pdf_url": "https://academic.oup.com/crohnscolitis360/article-pdf/8/4/otag086/72682910/otag086.pdf",
  "pmcid": "PMC13735508",
  "pmid": "42991151",
  "published": "2026-10-30",
  "publisher": "Oxford University Press",
  "ris": "https://research.draconitic.com/paper/5apzj33j3e24d.ris",
  "sources": [
    {
      "first_seen": "2026-11-09T12:21:10Z",
      "native_id": "PMC13735508",
      "source": "pmc",
      "url": "https://doi.org/10.1093/crocol/otag086"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2715|Inflammatory Bowel Disease",
      "subfield": "general"
    }
  ],
  "title": "Comparative effectiveness of IL-12/23 and IL-23 inhibitors versus JAK inhibitors in patients with inflammatory bowel disease and hidradenitis suppurativa: a real-world propensity-matched analysis",
  "title_text": "Comparative effectiveness of IL-12/23 and IL-23 inhibitors versus JAK inhibitors in patients with inflammatory bowel disease and hidradenitis suppurativa: a real-world propensity-matched analysis",
  "type": "peer-reviewed",
  "updated_at": "2026-11-09T12:21:10Z",
  "url": "https://research.draconitic.com/paper/5apzj33j3e24d",
  "venue": "Crohn's & Colitis 360",
  "versions": []
}